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Highlights 
 Accuracy and NPV of DP-CBCT were higher than MDCT and MRI (94%vs78%; 92%vs30%, 
respectively) 
 Confirmed HCC visible only in DP-CBCT were 54/243 (22%)  
 Nodules’ diameter was higher in DP-CBCT than MDCT and MRI (mean increase 1.6 mm; + 7.5%, p< 
0.05) 
 
Abstract  
Purpose 
This study was directed to compare diagnostic accuracy of dual-phase cone beam computed tomography 
(DP-CBCT) vs pre-procedural second line imaging modality (SLIM [multidetector computed tomography and 
magnetic resonance imaging]) to detect and characterize hepatocellular carcinoma (HCC) in cirrhotic 
patients with indication for trans-arterial chemoembolization (TACE). 
Methods 
This is a single centre, retrospective, and observational study. Exclusion criteria were not-assisted DP-CBCT 
TACE, and unavailable follow-up SLIM. We evaluated 280 consecutive patients (January/2015-
Febraury/2019). Seventy-two patients were eligible. Three radiologists in consensus reviewed: pre-
procedural SLIM, DP-CBCT, and SLIM at follow-up, with 4 months of interval between each reading. Hyper-
vascular foci (HVF) were detected and characterized. Diameter was recorded. Radiological behaviour, 
according to LI‐RADS criteria, of HFV throughout follow-up time was the reference standard. Diagnostic 
accuracy was calculated for pre-procedural SLIM and DP-CBCT and evaluated through receiver operating 
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characteristic curve. HVF only visible on DP-CBCT (defined as occult) were analysed. Tumour diameters 
were compared. 
Results  
Median time between pre-procedural SLIM and DP-CBCT and between DP-CBCT and definitive radiological 
diagnosis of HVF were 46.0 days (95%CI 36.5-55.0) and 30.5 days (95%CI 29.0-33.0), respectively.  
DP-CBCT had a better diagnostic performance than pre-examination SLIM (sensitivity 99%vs78%; specificity 
89%vs85%; PPV 99%vs99%; NPV 92%vs30%; and accuracy 94%vs79%). DP-CBCT diagnosed 63 occult HVF. 
Occult HCC were 54/243 (22.2%). Six were occult angiomas. Three were false positive. Mean diameter was 
significantly higher in DP-CBCT vs pre-procedural SLIM (+7.5% [95%CI 3.7-11.3], p<0.05). 
Conclusions 
DP-CBCT has a better diagnostic accuracy and NPV than pre-procedural SLIM in cirrhotic patients with 
indication for TACE.  
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Highlights 
 Accuracy and NPV of DP-CBCT were higher than MDCT and MRI (94%vs78%; 92%vs30%, 
respectively) 
 Confirmed HCC visible only on DP-CBCT were 54/243 (22%)  
 Nodule’sdiameter was higher in DP-CBCT than MDCT and MRI (mean increase 1.6 mm; + 7.5%, p< 
0.05) 
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Abbreviations 
 
BCLC: Barcelona Clinic Liver Cancer trans-arterial chemoembolization  
CI: confidence intervals  
DP-CBCT: dual phase cone beam computed tomography  
HCC: hepatocellular carcinoma 
HVF: hyper-vascular foci  
MDCT: multidetector computed tomography 
MRI: magnetic resonance imaging 
ROC: received operator characteristic  
RS: reference standard  
SLIM: second-line imaging modalities  
TACE: trans-arterial chemoembolization 
US: ultra-sound 
 
 
 
  
Jo
urn
al 
Pre
-pr
oo
f
  
Main Body 
Introduction  
Hepatocellular carcinoma (HCC) is the fifth most common cancer in the world, accounting for 7% of all 
cancer-related deaths and showing  an increasing trend in the future[1]. In cirrhotic patients, 6-month 
abdominal ultrasound (US) (sensitivity 58-89%; specificity > 90%) represents the recommended surveillance 
method, while second-line imaging modalities (multi-detector computed tomography [MDCT] and magnetic 
resonance imaging [MRI]) are only reserved for better lesion’s characterization [2, 3]. In cirrhotic patients 
with HCC, the imaging interval should be reduced to 3-4 months [3]. Chou et al.  highlighted a sensitivity of 
84% (95% confidence intervals [CI]=59-95) and a specificity of 99% (95%CI=86-99) for MDCT in a per-patient 
surveillance setting [4]. In a meta-analysis published by Lee YJ et al., the diagnostic accuracy was higher for 
MRI than MDCT (80% vs 68%, p< 0.01) [5]. The sensitivity and specificity of MRI rose to 87% and 94% using 
hepatobiliary phase. [6]. However, the per-lesion sensitivity for sub-centimeter HCC was insufficient in both 
for MDCT and MRI (64% vs 77%; 73% vs 81%; p<0.05, respectively) [5].  
According to the Barcelona Clinic Liver Cancer (BCLC) classification [7], trans-arterial 
chemoembolization (TACE) is indicated for intermediate stage disease. Both Cardiovascular and 
Interventional Radiological Society of Europe[8] and Society of Interventional Radiology [9] quality 
improvement guidelines emphasized the role of cone-beam computed tomography (CBCT) in assisting TACE 
procedures. CBCT is an acquisition obtained by a rotation of an angiographic suite equipped with flat panel 
detector  without patient repositioning [10]. Furthermore, CBCT can be performed before TACE procedure 
and using contrast media injection as multiphasic imaging.  In particular, CBCT has gained attention as a 
helper tool for tumor detection, intraprocedural guidance and treatment assessment during TACE [10-12]. 
More specifically, dual-phase (DP) CBCT showed a sensitivity of 93.9% for HCC detection, when compared 
with MRI [13] and with CBCT early-arterial or delayed arterial phase (72 %; 87 %, respectively) [14].  
Moreover, authors report the ability of monophasic CBCT to depict more hyper-vascular foci (HVF) defined 
as occult nodules in respect to pre-procedural second-line imaging modalities (SLIM), (rate: 11.5-28.7%) 
[15, 16]. The rationale to compare the diagnostic performance of DP-CBCT vs SLIM is based on several 
hypotheses. Firstly, CBCT has higher contrast-to-noise ratio and spatial resolution respect to MDCT [15, 17]. 
Secondly, intra-arterial injection of contrast media in CBCT enhances the contrast-to-noise ratio of the 
HVF[18]. Third, a nodule with typical radiological behavior on multiphasic CBCT can be highly consistent 
with HCC. Thus, the potential advantage of delayed second-phase acquisitions relies on the possibility of 
intra-procedurally assessing the nature of HVF. 
The objective of this study is to evaluate and compare the diagnostic performance (sensitivity, 
specificity, positive and negative predictive value and accuracy) of DP-CBCT vs. pre-procedural SLIM, using 
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as reference standard (RS) the behavior of the hyper-vascular foci (HVF)[HCC and angioma] at SLIM follow-
up in cirrhotic patients undergoing TACE for HCC.  
Material and Methods 
This study was approved by the ethical institutional review board. Informed consent for the procedure as 
for anonymized publication was obtained from all the individual participants included in this study.  
The manuscript was drafted according to Standards for Reporting Diagnostic accuracy studies (STARD) 
guideline.[19] 
This is a cohort, retrospective single center study. We retrospectively reviewed all patients that underwent 
TACE since January 2015 (installation of CBCT software) to February 2019. The indication for TACE was 
given in all cases by a multidisciplinary board formed by a transplant surgeon, an interventional radiologist, 
a body radiologist, and a hepatologist. We included in the study all patients treated with DP-CBCT-assisted 
TACE. Exclusion criteria were a) TACE not assisted by DP-CBCT; and, b) no SLIM at follow-up (Figure 1).  
Second-line imaging modality (MDCT or MRI) protocol 
MDCT 
MDCT was performed using a 1st Generation Dual Source CT scanner (SOMATOM DEFINITION; Siemens, 
Erlangen, Germany). The phases included in the protocol were: unenhanced, late arterial, venous and 
delayed. Late arterial-phase delay was defined using bolus tracking with automated scan triggering (CARE 
Bolus CT; Siemens, Erlangen, Germany) with a delay of 18 s after trigger threshold of 150 HU in supra-
coeliac abdominal aorta. All patients received 1.7 mL/kg body weight of iomeprol (Iomeron 370; Bracco, 
Milan, Italy)[20]. Contrast media was administrated via a dual chamber mechanical power injector (Stellant 
D CT; Medrad, Indianola, Pennsylvania) at a rate of 4.5 mL/s in a antecubital vein (18 Gauge needle). The 
contrast bolus was followed by a flush of 40 ml saline at the same injection rate. The tube scan parameters 
were modulated using CARE Dose (Siemens, Erlangen, Germany) and CARE kV (Siemens, Erlangen, 
Germany) : voltage reference, 120 kVp; current reference,  210 mA; gantry rotation time, 0.33 seconds; 
pitch, 1; slice thickness, 3 mm[15].   
MRI 
MRI was performed at 3 T MR scanners (Discovery MR750. GE HealthCare, Milwaukee, WI, USA) with an 8-
channel phased array coils. Protocols included T2-weighted single-shot sequence, a T2-weighted fast spin-
echo sequence with fat saturation, and a transverse breath-hold 3D T1- weighted fat-suppressed spoiled 
gradient-recalled echo sequence before and after dynamic injection of contrast medium. A free-breathing, 
fat-suppressed, single-shot echoplanar diffusion-weighted MR sequence was obtained before contrast 
injection with b values of 0, 50, 400 and 800 s/mm2. A total of 0.05 mmol/kg of body weight (0.1 ml/kg) of 
Jo
urn
l P
-pr
oo
f
  
Gd-BOPTA or 0.025 mmol/kg of body weight (0.1 ml/ kg) of Gd-EOB-DTPA were administrated followed by 
15-ml saline solution flush were administered at 2 ml/s with a power injector. Post contrast images were 
acquired during the late hepatic arterial, hepatic venous, and late dynamic phases, respectively, as well as 
during the hepatobiliary phase. Timing for the initial post-contrast arterial phase acquisition was 
determined using an automated bolus detection technique (SmartPrep, General Electric). Hepatobiliary 
phase was acquired at 20 min (Gd-EOB-DTPA) or at 75 minutes (Gd-BOPTA) after injection[21].  
CBCT 
All the procedures were performed by the same interventional radiologist (BLIND, > 10 years of experience) 
in a dedicated angiography suite equipped with a ceiling-mounted angiographic C-arm system and a 30*40-
cm flat-panel detector (Artis Zee; Siemens, Erlangen, Germany). Digital subtracted angiography and CBCT 
were acquired using a power injector (Mark V ProVis; Medrad, Indianola, Pennsylvania) after the 4-F 
catheter had been positioned within the proper hepatic artery. CBCT protocol included: arterial and 
delayed phases. All intraprocedural cone-beam CT acquisitions were performed with the same contrast 
medium (Iomeron 370; Bracco, Milan, Italy) diluted at a 1:3 ratio with sterile saline solution to avoid streak 
artefacts. Power injector parameters were set to 4 mL/s and intraarterial injection lasted 15 seconds to 
maintain arterial tree enhancement during CBCT acquisition; first CBCT acquisition started after 8 seconds 
of injection, second delayed phase CBCT was acquired after 35 seconds from the beginning of the injection. 
The C-arm rotates 200° around the patient in 5 seconds, acquiring images every 0.8° at 60 frames per 
second for a total of 248 images; the estimated detector dose was 0.36 μGy per frame. Reconstruction 
images lead to a 512*512*387 matrix and isotropic resolution of 0.49 mm, resulting in a 25*25*19-cm field 
of view. The liver was positioned symmetrically in the isocenter of the C-arm rotation[15].  
Follow-up  
Scheduled second-line imaging modality (MDCT or MRI) followed the protocol of our Institution developed 
by multidisciplinary board, based on the European Association for the Study of the Liver (EASL) and the 
European Organization for Research and Treatment of Cancer (EORTC). In particular, the first imaging was 
performed at least after 1 month following TACE procedure, thereafter every three months [1, 22]. The 
proportion of patients experienced MRI or MDCT as pre-procedural or follow-up imaging reproduced the 
retrospective nature of the study by reflecting the real-life of a high-volume tertiary referral liver 
transplantation center. This distribution was due to machines availability, patients’ contraindications and 
patients’ preferences.  
Imaging evaluation  
Three different expert body radiologists (>7 years of experience) evaluated each dataset of imaging 
technique (pre-TACE second-line imaging modalities, intra-procedural DP-CBCT, or all the available SLIM 
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follow-up imaging), with 4 months between each modality assessment. In case of disagreement a 
consensus was found.   
The radiological diagnosis of HCCs was performed at MDCT/MRI according to typical radiological behavior 
of HVF in cirrhotic liver following LI-RADS criteria [23-26]. LI-RADS criteria[26] were adapted to DP-CBCT 
imaging, although these criteria were not specifically addressed for this radiological technique.  
Reference Standard (RS) was defined as the evolution of focal liver lesion throughout all available follow-up 
time until the evidence of typical radiological HCC appearance. All HVF and their diameter were recorded. If 
the radiological behavior of an HVF was still equivocal at the last follow-up SLIM, the nodule was 
considered as non-HCC.  
Study outcome measurements  
The primary outcome was the diagnostic performance for detection and characterization of HVF within the 
liver, in patients with HCC and an indication for TACE, for both pre-procedural SLIM and intra-procedural 
DP-CBCT. 
The secondary outcome was the analysis of occult HVF defined as a nodule visible at the intra-procedural 
DP-CBCT, confirmed by the RS, and not visible at the pre-procedural SLIM.  
The tertiary outcome was the diameter dimension comparison between pre-procedural SLIM, intra-
procedural DP-CBCT and RS. The diameter was measured in venous phase for SLIM and delayed phase for 
DP-CBCT 
Statistical analysis 
Dichotomous variables were reported as numbers and percentages. The Kolmogorov-Smirnov Z test was 
performed to assess normality distribution for all variables tested. Continuous normal variables were 
expressed as mean ± standard deviation. Continuous non-normal variables were expressed as median and 
95%CI. The Wilcoxon’s test and the Bland and Altman plot were used to compare the tumor diameter as 
paired between pre-procedural SLIM and intra-procedural DP-CBCT. The behavior of focal liver lesion in all 
the available follow-up second-line imaging modalities was considered the RS. The diagnostic performance 
of the pre-TACE second-line imaging modality and DP-CBCT were compared with the RS. Sensitivity, 
specificity, predictive positive value (PPV), predictive negative value (NPV) and accuracy were evaluated 
through a Receiver Operating Characteristic (ROC).  
The sample size was calculated using an expected area under the curve for DP-CBCT of 0.947 and for pre-
exam SLIM of 0.771 as previous published [27]. Alpha- and beta-errors were set at 0.01. According to these 
parameters, the calculated predicted sample size was of 161 HVF. Considering a 15% of cases expected to 
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be lost at follow-up, the minimum sample size required for the study was therefore set at 185 HVF. P values 
< 0.05 were considered statistically significant. 
Statistical analysis was performed, and the graph was plotted using MedCalc 8.0 software (MedCalc, 
Mariakerke, Belgium).  
Results  
We retrospectively reviewed 280 consecutive patients undergoing TACE from January 2015 to February 
2019. Two hundred and two patients were excluded from the final analysis because they were not treated 
with a DP-CBCT-assisted TACE. Of the remaining 78 patients treated with 97 DP-CBCT-assisted TACE 
procedures, four (five TACE) were further excluded because of non-availability of SLIM at follow-up. Among 
these latter patients, two were censored for liver transplantation. Lastly, 72 cases were enrolled for the 
final analysis. Of these, 11 patients performed more than one TACE (nine patients = two TACE; one patient= 
three TACE; one patient = six TACE for a total of 18 re-TACE) (see the detailed Figure 1). 
The demographic and TACE detailed information were given in Table 1. 
The median time between pre-examination SLIM and TACE was 46.0 days (95%CI 36.5-55.0). The median 
follow-up time to the definitive radiological diagnosis of occult foci was 30.5 days (95%CI 29.0-33.0) (see 
Figure 2. for time frame distribution). The median follow-up time was 9 months (95% CI 7.0-10.1).  
Diagnostic performance 
In the 72 patients enrolled in this study, pre-procedural SLIM detected 209 HVF. Of these, 193/209 (92.3%) 
were diagnosed as HCCs. In 33/193 (17.1%) lesions, the diagnosis was done using MRI. Among the detected 
lesions, 161/193 (83.4%) presented a diameter > 10 mm (median diameter 16.0 mm [95%CI 14.0-18.2, min 
6.0 mm, max 88.0 mm]).  
The intra-procedural DP-CBCT diagnosed 259 HVF, with 244 of them (94.2%) diagnosed as HCCs. Hundred-
ninety-two/244 (78.7%) lesions, had a diameter > 10 mm. The median diameter of the HCC at intra-
procedural CBCT was 15.0 mm (95%CI 13.8 to 17.0, min 6.0 mm, max 82.0 mm).  
Finally, 261 HVF were diagnosed at RS: among them, 243 (93.1%) were HCC, while the remaining 18 were 
hemangiomas.  
Compared with RS, the intra-procedural DP-CBCT had a better diagnostic performance than pre-
examination SLIM (sensitivity 99% vs 78%; specificity 89% vs 85%; PPN 98% vs 99%; NPV 92% vs 30%; and 
accuracy 94% vs 82%) (Table 1 and Figure 5 showed the detailed analysis).  
Intra-procedural DP-CBCT was able to diagnose 63 occult HVF. Among these, 57/63 (90.0%) presented a 
typical radiological behavior for HCC and, therefore, they were categorized as HCC. However, three of 57 
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(5.3%) lesions were identified as false positives due to the absence of significant wash-out at RS until the 
last available imaging (29, 28 and 28 days, respectively). The maximum diameter of these lesions was 23 
mm, 8 mm and 7 mm, respectively.  Therefore, according to RS, the true positive occult HCC were 54/243 
(22.2%). The median diameter of occult HCC was 10.0 mm (95%CI 9.0-11.0). In particular, 33/54 (61%) 
occult nodules had a maximum diameter >10 mm, with 16/33 (48.5%) being placed in another hepatic 
segment in respect to the target lesion, and 3/16 (18.9%) in the contralateral hepatic lobe (For more 
details, see Flowchart 2,Figure 3  and Figure 4). Among patients with occult HCCs, 32/38 (84%) were multi-
nodular and 6/38 (16%)  were uni-nodular at pre-procedural SLIM; the indications for TACE were: palliative 
16/38 (42%), bridging for liver transplantation 13/38 (34%), debulking for liver resection 3/38 (8%), and 
downstaging 6/38 (16%).  
The intra-procedural DP-CBCT diameter (mean 19.0 mm; 95%CI 16.3-21.0) was significantly larger as 
compared to the pre-procedural SLIM (mean 16.0 mm; 95%CI 15.0-19.7). The Bland-Altman plot (Figure 6) 
showed a significant systematic increase of the lesion diameter between intra-procedural CBCT and pre-
procedural SLIM (mean increase 1.6 mm; 95%CI 0.8-2.4) Reporting this datum in percentage, a mean 7.5%-
increase of the lesions was reported ([95%CI 3.7-11.3; p< 0.05). 
Discussion  
The main result of this study is that intra-procedural DP-CBCT has a better diagnostic performance if 
compared with pre-procedural SLIM in HVF detection and characterization (accuracy 98% vs 79%).   
The worldwide-accepted reference standard imaging  for diagnosis of HCC is the second-line non-invasive 
imaging (MRI, CT). These imaging modalities are known to have a diagnostic accuracy of 80% and 68%, 
respectively. However, we know that that these performances further decrease to 77% and 64%, 
respectively, when dealing with sub-centimetric HCC [5]. 
Other invasive alternatives have been proposed, namely a CT during hepatic arteriography (CTHA) or 
arterial portography (CTHP). These modalities, only applied in the subset of patients scheduled for 
treatment, had been investigated against Digital Subtraction Angiography (DSA) acquisition, demonstrating 
a clear superiority in terms of lesions identification (sensitivity CTHP 93.9%, CTHA 96.7%; CBCT pooled 
sensitivity 90% [95%VI 82%-95%]). [28-30].  
More recently, CBCT has gained a role in assisting TACE procedures [12, 14], but all the existing reports in 
literature were focused on CBCT sensitivity (pooled sensitivity 90%[95%CI 82%-95%]); in case of diameter < 
10 mm, sensitivity 94.5%) [30, 31]. Moreover, some Authors reported the ability of CBCT, generally in 
arterial phase only, to detect occult hepatic lesions (ranging: 11.5-28.7%) [15, 16]. However, the lack of 
delayed-phase imaging in the reported studies limited lesions’ characterization (specificity). Therefore, the 
introduction of a biphasic approach in CBCT, including arterial and delayed phase, may combine the ability 
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to detect with the possibility to characterize HVF by applying the LI-RADS criteria[26] to DP-CBCT. Thus, by 
introducing in clinical practice the DP-CBCT imaging, and by applying the same SLIM radiological 
methodology to diagnose HVF, it could be possible to intra-procedurally characterize occult nodules. In 
order to strengthen this evidence, all the lesions in the present study were followed-up until a definitive 
radiological diagnosis was reached. By employing this approach, intraprocedural DP-CBCT detected 259 
HVF, with 244 of them presenting a typical radiological wash-out and, therefore, appearing to address the 
features of an HCC. Thanks to these results, this approach led to a sensitivity, specificity, PPV and NPV of 
99%, 89%, 99%, and 92%, respectively. Despite guidelines[1]  did not consider reliable the radiological 
diagnosis of HVF with a diameter < 10 mm, intra-procedural DP-CBCT had sensitivity 100%, specificity 78%, 
PPV 95%, NPV 100% and accuracy 89% in this specific subset.  
Comparing the intra- with the pre-procedural images, a datum emerged that 57 HCC were diagnosed only 
with DP-CBCT. More in detail, 54/57 (94.7%) lesions were confirmed by RS, reflecting the superiority in NPV 
of intra-procedural DP-CBCT over pre-procedural SLIM (92% vs overall SLIM 29.9%; vs MRI 30.8%; vs MDCT 
29.7%). Only three of 57 (5.3%) lesions were not confirmed by RS (33/54 [61.1%] > 10 mm; 21/54 [38.9%] 
<10 mm). All the false positive HCC were HVF both in DP-CBCT and in RS, but without significant wash-out 
in RS. The diameter and the maximum follow-up time were 23, 9 and 8 mm, and 29, 28 and 28 days, 
respectively. These findings may reflect an incomplete maturation phase of the malignant process and 
could not be objectified due to unavailable follow-up. Since this approach to DP-CBCT imaging (using as 
diagnostic tool by applying LI-RADS criteria) was still under investigation the occult nodules observed were 
never treated during the same TACE procedure.  
The stratification of occult nodules by diameter may have a clinical implication: occult HCC > 10 mm could 
represent a potential target for adjunctive treatment whereas occult HCC < 10 mm may identify impact on 
surveillance time frame. Further studies are necessary to better understand these implications.  
According to Bland-Altman analysis, intra-procedural DP-CBCT systematically oversized the hyper-vascular 
HCC over the pre-procedural SLIM (mean diameter difference 1.6 mm or + 7.5%). This finding is consistent 
with previous reports [15], potentially reflecting the intrinsically higher signal-to-noise ratio of CBCT over 
MDCT, and the intra-arterial injection of contrast media.  
Differences in HCC’s detection rate and dimensions between pre-procedural SLIM and DP-CBCT may have a 
strong impact on the management of cirrhotic patients with HCC. In fact, both guidelines for HCC 
management [7, 32-34] and for liver transplantation [35] consider these two features as a cornerstone in 
the decision making process. Therefore, a more precise staging of the disease could facilitate a tailored 
treatment.  
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Our study presents some limitations. Firstly, the nature of the study is retrospective and observational. 
Secondly, the median time frame between pre-procedural SLIM and DP-CBCT was 46.0 days (95%CI 36.5-
55.0), thus potentially justifying the differences of the lesion diameters observed in our results. However, 
we should underline that HCC is known to have a slow tumor volume doubling time (127.6 ± 128.7 days), 
typically longer respect to the time frame observed in our analysis [36]. Thirdly, being the design of this 
study retrospective and pragmatic (not a trial), it reflected the everyday clinical activity of a high-volume 
radiology department within a transplant center in which different SLIM are offered. Lastly, all dataset of 
images were reviewed in consensus and not in blinded fashion by three radiologist. 
 
Conclusion 
The present study highlights the better diagnostic performance of intra-procedural DP-CBCT over pre-
procedural SLIM. This result presents relevant potential clinical implications in terms of treatment and 
surveillance timing.  
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Figure and Table Captions 
Figure 1. Flowchart 1.  
Figure1. Detailed Flowchart of the study. The number of nodules was calculated based on follow-up SLIM 
 
Figure 2. Time Frame  
Figure 2 showed the time between pre-procedural second line imaging modality (SLIM) and trans-arterial 
chemoembolization (TACE) among all patients (first column) and the required minimum time for the 
definitive radiological diagnosis only in patients with occult HCCs (second columns) 
 
Figure 3. Flowchart 2.  
Figure 3 showed the flowchart of occult hyper-vascular foci distribution. HCC hepatocellular carcinoma; DM 
diameter maximum 
 
Figure 4. Clinical Case 
Figure 4 Clinical case of 54 years old woman with single HCC  in V-VIII hepatic segment  (arrow) showed at 
magnetic resonance imaging in arterial (a) and hepatobiliary phase (b), without any other nodules; the cone 
beam computed tomography performed during TACE after 31 days evidenced the target nodule (arrow ) 
and another hyper-vascular focality (arrowhead) in the II hepatic segment with wash-in (c) and wash-out in 
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the delayed phase (d) suspected for occult HCC. The follow-up CT confirmed the findings with typical rapid 
wash-in (e) and wash-out (f) (arrowhead) consisted with HCC. The arrow in figure e and f highlighted the 
complete response dot the target nodules 
 
Figure 5. ROC Curve Comparison 
Figure 5 ROC curve analysis. HCC hepatocellular carcinoma; CBCT cone beam computed tomography; SLIM 
second line imaging modality; DM diameter maximum; MRI magnetic resonance imaging; MDCT 
multidetector computed tomography 
 
Figure 6. Bland and Altman plot  
Figure 6 The Bland and Altman plot showed mean diameter differences between intra-procedural CBCT and 
pre-procedural SLIM). DM: diameter maximum; CBCT: come beam CT; SLIM: second line imaging modality. 
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Table 1. Clinical demographic  
TACE Trans arterial chemoembolization; SD Standard Deviation; M Male; F Female; HCV Hepatitis C virus; 
HBV Hepatitis B virus; NASH Non-alcoholic steatohepatitis; MELD Model for End-Stage Liver Disease; 
Patient number N= 72 
Number of TACE performed N= 90 
Nodules Dimension 
Maximum diameter. mm. (mean value 95%CI. range) 
 
16.0 mm (15.0-19.7; 6.0-89.0)  
Age, year (mean value ± SD. range) 66.5± 12.8 (41-89) 
Sex (M/F) 50/22 
Child Pugh N (%) 
A5 
A6 
B7 
B8 
B9 
 
34 (47.2) 
12 (16.7) 
18 (25) 
7 (9.7) 
1 (1.4) 
BCLC N (%) 
A 
B 
 
46 (63.9)  
26 (36.1) 
Etiology: N (%) 
HCV 
HBV  
Alcohol related cirrhosis 
Cryptogenetic cirrhosis 
NASH 
 
29 (40.3) 
19 (26.4) 
15 (20.8) 
5 (6.9) 
4 (5.6) 
MELD: N (%) 
<10 
≥10 
 
42 (58.3) 
30 (41.7) 
MELDNa: N (%) 
<10 
≥10 
 
48 (66.7) 
24 (33.3) 
Mono-focal N (%) / multi-focal disease N (%) 22 (30.6)/ 50 (69.4) 
Indications for TACE N (%) 
Palliative 
Bridging 
Debulking 
Downstaging 
 
 
48 (53.3) 
25 (27.8) 
8 (8.9) 
9 (10.0)  
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Table 2. Diagnostic performance 
RS: reference standard; CI 95%: Confidence interval 95%; SLIM second line imaging modality; HVF hyper-
vascular foci; MRI: magnetic resonance imaging; MDCT: multidetector computed tomography; The 
diagnostic performance of MRI pre-procedural < 30 days was not determined due to few data available.  
Diagnostic exams vs 
RS 
Sensitivity 
(%) [CI95%] 
Specificity 
(%) [CI95%] 
Positive 
predictive value 
(%) [CI95%] 
Negative 
predictive 
value 
(%) [CI95%] 
Accuracy 
(%) [CI95%] 
SLIM pre-procedural 77.78 [72.0 -
 82.8] 
85.19 
[66.3 - 95.8] 
97.9 
[95.0 - 99.2] 
29.9 
[24.3 - 36.1] 
81.5 [76.3 – 
85.9] 
SLIM pre-procedural 
HVF >10 mm 
86.91 
[81.3 - 91.3] 
100.00 
[29.2 -
 100.0] 
100.0 
[100 - 100] 
10.7 
[7.7 - 14.7] 
93.5 
[89.0 -96.5] 
SLIM pre-procedural 
<30 days 
87.32 [77.3 -
 94.0] 
66.67 
[22.3 - 95.7] 
96.9 
[90.9 - 99.0] 
30.8 
[16.2 - 50.5] 
77.0 
[66.0 – 85.8] 
SLIM pre-procedural 
HVF >10 mm <30 
days 
77.50 
[71.7 - 82.6] 
100.00 
[79.4 -
 100.0] 
100.0 
[100 - 100] 
22.9 
[19.0 - 27.3] 
88.8 
[84.2 – 92.3] 
MRI pre-procedural 78.57 
[63.2 - 89.7] 
100.00 
[39.8 -
 100.0] 
100.0 
[100 - 100] 
30.8 
[19.9 - 44.2] 
89.3 
[76.6 – 96.5] 
MDCT pre-
procedural 
77.61 
[71.2 - 83.2] 
82.61 
[61.2 - 95.0] 
97.5 
[94.1 - 99.0] 
29.7 
[23.5 - 36.7] 
80.1 
[74.3 - 
0.851] 
CBCT 99.18 [97.1 -
 99.9] 
88.89 [70.8 -
 97.6] 
98.8 
[96.5 - 99.6] 
92.3 [75.0 -
 98.0] 
94.0 
[90.5 – 96.5] 
CBCT HVF >10 mm 100.00 [98.1 -
 100.0] 
66.67 
[9.4 - 99.2] 
99.5 
[97.5 - 99.9] 
100.0 
[100 - 100] 
83.3 
[77.3 – 88.3] 
CBCT HVF <10 mm 100.00 [90.7 -
 100.0] 
77.78 
[40.0 - 92.7] 
95.0  
[84.8 – 98.5] 
100.0 
[100 - 100] 
88.9 
[76.3-96.2] 
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